Copyright
©The Author(s) 2017.
World J Gastrointest Oncol. Jul 15, 2017; 9(7): 268-280
Published online Jul 15, 2017. doi: 10.4251/wjgo.v9.i7.268
Published online Jul 15, 2017. doi: 10.4251/wjgo.v9.i7.268
FGFR fusion partner | Frequency | Ref. |
FGFR2-AHCYL | 7/102 (7%) | [56] |
FGFR2-BICC1 | 2/102 (2%) | [56] |
41/107 (38%) | [57] | |
1/28 (4%) | [66] | |
FGFR2-PPHLN1 | 17/107 (16%) | [57] |
FGFR2-MGEA5 | 1/6 (17%) | [62] |
FGFR2-TACC3 | 1/6 (17%) | [62] |
1/28 (4%) | [66] | |
FGFR-KIAA1598 | 1/28 (4%) | [66] |
- Citation: Kayhanian H, Smyth EC, Braconi C. Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2017; 9(7): 268-280
- URL: https://www.wjgnet.com/1948-5204/full/v9/i7/268.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v9.i7.268